Latest articlesAll articles
In this episode, we delve into some of the key insights provided by our guests, as well as other notable conversati… twitter.com/i/web/status/1…
Posted 26 April
We are pleased to announce @EMJReviews has been awarded the Queen’s Award for Enterprise for International Trade. F… twitter.com/i/web/status/1…
Posted 21 April
This article presents a case of a 47-year-old male with medullary cancer of the pancreas treated surgically.… twitter.com/i/web/status/1…
Posted 13 April
This expert roundtable discussion will cover various topics including new mechanisms of action, new trends, and dat… twitter.com/i/web/status/1…
Posted 12 April
Join us for a roundtable discussion to gain a deeper understanding of emerging data from the latest European Crohn’… twitter.com/i/web/status/1…
Posted 11 April
Latest abstractsAll abstracts
Dietitians Could Help with the Demand in Gastrointestinal Services
DIETITIANS could provide outpatient medical gastroenterology clinics for patients with irritable bowel syndrome (IBS). Evidence for this was presented on 3rd October 2021 at the virtual UEG Week by Christian Shaw, Sheffield Teaching Hospital NHS Foundation Trust, UK.
Ursodeoxycholic Acid to Treat Gallstones in Bariatric Surgery Patients
BARIATRIC surgery is a safe and long-term treatment for weight loss; however, the rapid weight loss it induces is a major risk factor for the formation of cholesterol gallstones. The causal link between weight-loss and gallstone formation is not fully understood, but an important factor is the consequential imbalance in biliary lipids. Cholecystectomy at the time of bariatric surgery is the current standard treatment for gallstones, the evidence for the use of ursodeoxycholic acid (UDCA) prophylaxis is still under debate. Research led by Sylke Haal, Amsterdam UMC, University of Amsterdam, the Netherlands, was conducted to provide evidence for whether UDCA reduces the occurrence of gallstone disease after bariatric surgery.
Genetic Changes in Oesophageal Adenocarcinoma During Neoadjuvant Treatment
OESOPHAGEAL cancer (OAC) is the seventh most common cancer in the world. Patients with this cancer are commonly treated with neoadjuvant chemotherapy, radiotherapy, or surgery. Unfortunately, over half of tumours are resistant to neoadjuvant therapy and survival rates are poor. A novel study, shared at the UEG Week Virtual, aimed to understand the genetic and transcriptomic changes in OAC.
Outcomes Following Duodenectomy in Patients with Familial Adenomatous Polyposis
DETERMINING the timing of surgery remains a challenge for patients with adenomatous polyposis, an inherited autosomal dominant condition. This abstract was presented by Isabel Martin, St Mark’s Hospital, London, UK, at UEG Week Virtual, who noted: “Ideally intervention takes place before cancer is diagnosed, as afterwards the outcomes are very poor.” Upper gastrointestinal endoscopic surveillance was recommended following pancreaticoduodenectomy (PD) or pancreas-sparing duodenectomy (PSD). This review is of importance in a field where long-term data is lacking.